Lyme Disease Antibodies (IgG, IgM), Immunoblot - CSF
Use
Immunoblot testing qualitatively examines, with high specificity, antibodies (IgG and IgM) against Borrelia burgdorferi in cerebrospinal fluid (CSF). It is appropriate for confirmation of reactive or equivocal serologic screening tests in central nervous system (CNS) involvement suspected of Lyme disease. The test helps support the diagnosis of Lyme neuroborreliosis when CSF antibody detection is clinically indicated.
Special Instructions
Not provided.
Limitations
Serologic testing may yield false-negative results during early stages of infection before antibody levels have risen to detectable concentrations. Antibodies may persist long after infection has cleared, so positive results do not confirm active infection. Cross-reactivity with other spirochetal or autoimmune conditions can cause false-positive immunoblot results.
Methodology
Immunoassay (Immunoblot)
Biomarkers
Result Turnaround Time
1-4 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
0.5 mL
Minimum Volume
0.2 mL
Container
Sterile container
Collection Instructions
Do not centrifuge cerebrospinal fluid.
Storage Instructions
Room temperature
Causes for Rejection
Gross contamination; severe hemolysis; quantity not sufficient for analysis
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |